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RESUMEN
Objetivo: La presente investigación estudia EL efecto de polimetacrilato Eudragit RSPO, Y RLPO 
EUDRAGIT compritol 888 ATO en el perfil de liberación de un farmaco altamente soluble en agua como 
es el clorhidrato de metformina (MET).
Materiales y Métodos: Las dispersiones sólidas se prepararon utilizando fármaco:polímero en 
proporciones 1:1 y 1:5 por técnicas de coprecipitación y coevaporation. Las dispersiones sólidas se 
caracterizaron por espectroscopía de infrarrojo (IR), calorimetría diferencial de barrido (DSC), difracción 
de rayos X (DRX), así como uniformidad de contenido, los estudios de disolución in vitro de 0,1 N HCl 
pH 1.2 , tampón fosfato pH 6.8 .
Resultados y Discusión: Los resultados de los estudios sugiere que hubo desaparición progresiva o 
cambios de los picos en IR, señales termotrópicos de fármaco en coevaporados y coprecipitados con 
aumento de la cantidad de polímeros de difracción de rayos X. Por otra parte, la liberación in vitro de 
MET altamente soluble en agua podría extenderse a rangos más altos de fármaco : polímero.
Conclusión: Se resume Y RLPO EUDRAGIT que había mayor capacidad de liberación de fármacos de 
Eudragit RSPO y Comproitol 888 y su coevaporates en 1:5:polímero relación drogas (F11) extendidos 
liberación de fármacos con tasas comparativamente mayor disolución (92,15 % liberación de fármacos a 
las 12 horas) cercano a cero orden cinética (r2 = 0,9822 ).
PALABRAS CLAVE: Clorhidrato de metformina, Dispersión, Fármaco hidrosoluble, 
Liberación, 
ABSTRACT
Aims: The present investigation studied effect of polymethacrylates Eudragit RSPO, Eudragit RLPO and 
compritol 888 ATO on release profile of highly water soluble drug metformin hydrochloride (MET). 
Materials and Methods: The solid dispersions were prepared using drug:polymer ratios 1:1 and 1:5 
by coevaporation and coprecipitation techniques. Solid dispersions were characterized by infrared 
Spectroscopy (IR), differential scanning  calorimetry (DSC), X-ray diffractometry (XRD) as well as content 
uniformity, in vitro dissolution  studies in 0.1 N HCl pH 1.2, phosphate  buffer pH 6.8. 
Results and Discussion: Results of the studies suggested that there were progressive disappearance or 
changes of prominent peaks in IR, X-ray diffraction and thermotropic  drug signals in coevaporates and 
coprecipitates with increased amount of polymers. Moreover, the in vitro release of highly water soluble 
MET could be extended at higher drug:polymer ratios. 
Conclusion: It was summarized that Eudragit RLPO had greater capacity of drug release than Eudragit 
RSPO and Comproitol 888 and its coevaporates in 1:5 drug:polymer ratio (F11) displayed extended drug 
release with comparatively higher dissolution rates (92.15 % drug release at 12 hour) following near Zero 
order kinetics (r2 =0.9822).
KEY WORDS: Extended release, Highly water soluble drug, Metformin hydrochloride, Solid 
dispersion
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INTRODUCTION
Many problems are associated with conventional multiple 
dosing regimen of long acting therapy, such as systemic 
accumulation of the drug leading to side effects or 
toxicities, irregular profile of the plasma drug level, and 
poor patient compliance. Controlled release drug delivery 
systems have the potential of solving these problems. 
Controlled release systems are the methods that can 
achieve therapeutically effective concentration of drug 
in the systemic circulation over an extended period of 
time with better patient compliance. Various approaches 
ranging from coated tablets and gels to biodegradable 
microparticles and osmotic systems have been used in an 
attempt to sustain the drug release from dosage forms. In 
most of the controlled release formulations, immediately 
upon placement in the release medium, an initial large 
bolus of drug is released before the release rate reaches 
a stable profile. This phenomenon is typically referred to 
as ‘burst release’. Burst release leads to higher initial drug 
delivery and also reduces the effective life time of the 
device. For controlling drug release, the solid dispersion 
method is an alternative approach1.
The solid dispersion approach is commonly used to 
improve the dissolution properties of poorly water soluble 
drugs using hydrophilic polymeric carriers as dispersing 
agents. More recently, several studies on solid dispersions 
have been carried out using water insoluble carriers to 
produce sustained release pharmaceutical forms of freely 
water soluble drugs2-4. For this goal, different types of 
polymethacrylates (Eudragit) have been considered. 
The most interesting among acrylic polymers are highly 
permeable Eudragit RL and low permeable Eudragit RS, 
both are neutral copolymers of poly (ethylacrylate, methyl 
methacrylate) and trimethyl aminoethyl methacrylate 
chloride and are insoluble in water and digestive juices, but 
both swell and are permeable. Extended release systems 
are the methods that can achieve therapeutically effective 
concentrations of drug in systemic circulation over an 
extended period of time. Various researchers used the 
solid dispersion method for this purpose5-8. A combination 
of solid dispersion and extended release is one of the 
attractive approaches since supersaturation of the drugs 
can be achieved by employing solid dispersion technique. 
Keeping in mind all these facts, extending or controlling 
the release of a highly water soluble BCS class I (high 
solubility, high permeability)drug seems to be interesting 
using solid dispersion approach employing lipophilic 
carriers. Therefore, in present study, Eudragit RLPO and 
Eudragit RSPO have been used as retardants to prepare 
a novel extended release system of highly water soluble 
medicine metformin hydrochloride using coevaporation 
and coprecipitation techniques in order to extend their 
dissolution rates and to study the influence of type and 
concentration of Eudragit polymers on release profiles of 
the developed solid dispersion systems.  
MATERIALS AND METHODS
Materials:
Metformin hydrochloride (MET) was gifted by Microlabs, 
Bangalore, India. Compritol 888 ATO (Compritol) was 
obtained ex gratia by Gattefosse, France. Eudragit RSPO 
(RSPO) and Eudragit RLPO (RLPO) were supplied as 
gift samples from Roehm Pharma, Germany. All other 
chemicals used were of analytical grade and double 
distilled water was used throughout the studies.
Methods:
Preparation of metformin hcl solid dispersions
Solid dispersions were prepared using three different 
polymers RSPO, RLPO and Compritol 888 ATO at two 
different drug:polymer ratios 1:1 and 1:5 using physical 
mixing, coevaporation and coprecipitation methods. 
Formulations were coded using method, polymer and 
ratio.   
Physical mixing method 
Physical mixtures were prepared by mixing the powdered 
drug and polymers in a mortar. Metformin HCl and 
polymers in two different weight ratios (1:1 and 1:5) 
were accurately weighed, mixed well in mortar for 5 
minutes, sifted through sieve no.80 and stored in vacuum 
desiccators. 
Coevaporation method 
Metformin HCl and different carriers were taken in 
different ratios (1:1 and 1:5), mixed well and dissolved in 
20ml mixture (1:1) of dichloromethane and chloroform. 
The solvent was evaporated at 400C for 5 minutes, dried 
completely in vacuum desiccators. The solid sample was 
pulverized gently in a mortar and passed through sieve no. 80.
Coprecipitation method
Metformin HCl and different carriers were taken in 
different ratios (1:1 and 1:5), mixed well and dissolved 
in 20ml of dichloromethane and methanol. These masses 
were further transferred to 30 ml diethyl ether at 00C while 
being gently stirred. The precipitates were filtered using 
qualitative filter paper, spreaded on petri plate and dried 
to a constant weight. The dried samples were pulverized, 
screened through 80 mesh size sieve and stored in vacuum 
desiccators.
24-31.
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Characterization of solid dispersion systems
IR spectroscopy
IR spectra of pure drug, polymers and formulated solid 
dispersions were obtained with a IR spectrophotometer 
(shimadzu IR-prestize-21) using KBR disks. The scanning 
range used was 4000 to 400cm-1 at a scan of 1 minute.
Differential scanning calorimetry
Thermal analysis was performed on the drug, polymers and 
solid dispersions using a PERKIN-ELMER DSC-7. Samples 
(10-15mg) were weighed and scaled into 40μL aluminium 
pans. DSC runs were conducted over a temperature range 
of 700C to 2500C at a rate of 10 °C / minute in nitrogen 
atmosphere.
X-Ray powder diffractrometry 
Differential patterns of drug, polymers and solid dispersions 
were recorded (PW 3040/60 X Pert PRO, Netherlands). A 
voltage of 40 kv and a current of 30 mA for the generator 
was used, with Cu as the tube anode material. The solid 
samples were exposed to Cu-Ka radiation (a1 =1.54060 A, 
with an α1/α2 ratio of 0.5), over a range of 2θ angles from 
100C to 300C, at an angular speed of (2θ) per minute.
Determination of drug content 
Ten mg of each of the solid dispersion was accurately 
weighed and dissolved in 10 ml phosphate buffer pH 
6.8 and filtered. One ml of sample was withdrawn from 
each volumetric flask, suitably diluted and assayed 
spectrophotometrically at 232 nm. The amount of MET in 
each sample was computed using calibration curve based 
on standard solution in phosphate buffer. Results were 
expressed both as the drug content (mg incorporated drug) 
and percent drug incorporation (actual amount of drug 
in solid dispersion vs initially 
added amount). The studies 
were conducted in triplicate.
Determination of in vitro drug 
release of solid dispersions
In vitro dissolution was 
performed using USP dissolution 
rate test apparatus I in 900ml of 
simulated gastric fluid (0.1 N 
HCl pH 1.2), simulated intestinal 
fluid (phosphate buffer pH 6.8) 
at an agitation rate of 100 rpm. 
The temperature of medium 
was maintained at 37±0.50C. 
An amount of solid dispersions 
equivalent to 75mg of drug were 
filled in transparent hard gelatin capsules and analyzed for 
drug release. At predetermined time intervals, aliquotes 
were withdrawn and replaced with an equal volume of 
fresh dissolution medium to maintain a constant dissolution 
volume. The samples were filtered, suitably diluted and 
assayed spectrophotometrically at 232nm.
Evaluation of release kinetic of solid dispersions
Data obtained from in vitro release studies was fitted to 
various kinetic equations to find out the mechanism of MET 
release form polymeric matrix system. The kinetic models 
used were zero order, First order, Higuchi and peppas 
model. The following plots were made: Qt Vs t (Zero order 
kinetic model), log (Qo-Qt) Vs t (first orderkinetic modael), 
Qt and Vs square root of   t(Higuchi model)where Qt is the 
amount of drug release at time t and Qo is the amount of 
drug present in solid dispersion, Q=Ktn (Peppas model) 
where Q is the amount of drug  release; t time; k is constant 
incorporating structural and geometrical characteristic of 
the release device and n is the exponent indicative of the 
mechanism of release. Plots were subjected to regression 
analysis to find out the regression coefficient and hence the 
order of release.
RESULTS AND DISCUSSION
IR studies revealed that MET showed two typical bands 
at 3369 and 3296 cm–1 due to N-H stretching (1°), a band 
at 3170 cm–1 due to N-H stretching (2°), and characteristics 
bands at 1626 and 1567 cm–1 assigned to C=N stretching. 
These peaks were unchanged in physical mixtures but 
disappeared in corresponding coevaporates (Fig. 1). These 
results suggested the possibility of intermolecular hydrogen 
bonding between PHC and RLPO in coevaporates. These 
interactions were made while the molecules were in 
Figure 1. Comparative IR spectra of MET, RLPO, formulations F10 and F11.
24-31.
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solution that is when the distances between the molecules 
were so small that association between the functional 
groups was possible9.
The DSC curves of pure MET exhibited an initially flat 
profile, followed by a single sharp endothermic peak 
representing the melting of the substance in the range 
223–237°C (Tonset = 231.2, Tpeak = 233.33 and ΔHfusion = -313.51 
J/g). DSC curves of both RLPO and RSPO exhibited a flat 
thermal profile, indicative of the completely amorphous 
nature of these two polymers. The thermal curves of 
binary drug–polymer(s) mixtures, obtained by simple 
blending corresponded to the superimposition of those of 
the single components, indicating the absence of solid-state 
interactions and allowing assessment of drug–polymers 
compatibility in all the examined formulations (Fig.2).
XRD analysis of pure RSPO and RLPO confirmed their 
amorphous nature whereas the pure drug showed the 
diffractographic profiles of a crystalline product. When 
solid dispersions prepared with different polymer fractions 
were compared, it was clear that the systems prepared 
with lower polymer amounts still showed the typical 
signals of crystals, while increasing the polymer ratio 
progressively weakened their intensity. Crystallinity of 
drug in solid dispersion was always less than that observed 
in corresponding physical mixtures (Fig.3).
The actual drug contents of prepared solid dispersions 
in different samples revealed 95-100% of expected values 
with reproducible results. The drug content was uniform 
in all solid dispersion systems and was in good agreement 
with theoretical drug content (Table 1).
Figure 2. Comparative DSC thermograms of MET, RLPO, formulations F10  and F11
The release profiles of MET from the solid dispersion 
systems F7 to F12 were compared (Fig. 4). The dispersions 
of drugs in polymer matrices strongly influenced their 
dissolution rates which appeared lower and more gradual 
than that of pure drug. The significant dissolution 
observed for most solid dispersions containing MET at 
simulated gastric fluid became protonated at the acidic 
buffer (pH 1.2) and made drug readily soluble, While in 
phosphate buffer (pH 6.8), solid dispersions were found 
to extend drug release up to 12 hours because of decrease 
in solubility as compared with other media. In phosphate 
buffer (pH 6.8), polymer dispersion of MET with RLPO 
usually displayed higher dissolution rates than F1-F6 
formulations having RSPO because of greater quaternary 
ammonium group content, which act as activity sites for 
electrostatic interactions. Eudragit RSPO is only permeable 
to water; hence drug release was relatively retarded with 
respect to freely permeable Eudragit RLPO. On the other 
hand, Eudragit RSPO swells in aqueous natural and 
artificial digestive juices, rendering itself permeable to these 
liquids. The mechanism of drug release would probably 
be through direct dissolution of partially embedded drug 
followed by diffusion of embedded drug via the matrix 
pores. These results might be due to the fact that Eudragit 
RLPO is capable of swelling without disintegration at pH 
1.2-6.8 and due to its permeability, permeation occurred. 
Coprecipitates containing Eudragit RSPO at higher drug to 
polymer ratios were able to slow down the diffusion rate 
of drug.
On analyzing regression coefficient values of all batches, it 
was found that F11 followed Zero order kinetics (r2 = 0.9822). 
To confirm diffusion, the data were fitted to Korsemeyer-
24-31.
Dahiya S, Onker R
29Ars Pharm. 2015; 56(1):
Figure 3. Comparative X-ray diffractograms of MET, RLPO, formulations F10 and F11 
Table 1. Drug content studies of solid dispersion formulations.
CONCLUSION 
The results revealed that the preparation conditions did 
not make polymorphic changes or amorphization of drug 
within the polymer network and higher amount of polymer 
displayed diluting effect on physicochemical properties of 
drug within prepared dispersions. The release of highly 
water soluble MET could not be controlled at lower 
Formulation 
Number
Formulation 
Code
Loading efficiency (mg)
Percent drug incorporationTheoretical
drug content (%)
Actual drug content 
(%)#
F1 PMRS1 50.00 46.57±0.001 98.17
F2 CERS1 50.00 45.48±0.003 98.32
F3 CPRS1 50.00 45.83±0.002 99.49
F4 PMRS5 16.67 15.21±0.003 98.13
F5 CERS5 16.67 13.11±0.001 99.99
F6 CPRS5 16.67 13.45±0.002 99.85
F7 PMRL1 50.00 47.35±0.002 95.24
F8 CERL1 50.00 46.55±0.001 97.16
F9 CPRL1 50.00 45.14±0.003 99.19
F10 PMRL5 16.67 14.26±0.004 95.45
F11 CERL5 16.67 15.26±0.002 98.52
F12 CPRL5 16.67 13.65±0.001 97.12
F13 PMCT1 50.00 47.16±0.003 98.16
F14 CECT1 50.00 46.25±0.002 100.27
F15 CPCT1 50.00 45.28±0.002 96.65
F16 PMCT5 16.67 14.33±0.001 97.82
F17 CECT5 16.67 13.03±0.002 98.18
F18 CPCT5 16.67 15.13±0.001 99.12
#average of three determinations
Peppas equation. The model fitting parameters of solid 
dispersion formulations are summarized in Table 2. The 
formulations with 0.5<n<1 appeared to indicate non-
Fickian type of release mechanism meaning that the drug 
release couples diffusion with erosion so called anomalous 
diffusion and may indicate that the release is controlled by 
more than one process. 
24-31.
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polymer ratio. Drug:RLPO coevaporates in 1:5 ratio could 
extend release of freely water soluble drug and could be 
suggested to be incorporated to formulate suitable oral 
solid dosage forms such as capsules or tablets. The studies 
provided better forecasting and understanding of solid 
dispersions as an alternative approach to controlled drug 
delivery and possibly utilizing such particulate systems to 
develop better delivery systems over existing ones. 
Figure 4. Comparative drug release profiles of formulations F7-F12 
Table 2. Model fitting parameters of solid dispersion formulations 
Formulation 
Number
Zero order First order Higuchi Korsmeyer-Peppas
r2 k r2 k r2 k r2 n
F1 0.7508 3.3279 0.3322 0.0388 0.7762 13.8432 0.6168 0.8116
F2 0.6329 2.5427 0.4035 0.0478 0.7222 11.6739 0.5953 0.769
F3 0.5486 2.0835 0.4346 0.0453 0.7174 10.9613 0.5757 0.7335
F4 0.8295 4.0693 0.2705 0.0320 0.8337 16.2556 0.6696 0.8805
F5 0.6678 2.8125 0.3832 0.0452 0.8157 1.3.8216 0.6261 0.8172
F6 0.6073 2.1933 0.4221 0.5186 0.7565 10.9929 0.6040 0.7560
F7 0.8038 3.7509 0.2857 0.0332 0.7675 14.4099 0.6327 0.8370
F8 0.8451 4.4393 0.1967 0.0225 0.8202 17.3365 0.6539 0.8836
F9 0.6314 2.5093 0.4036 0.0479 0.6963 11.1330 0.5868 0.7570
F10 0.9347 4.8702 0.1949 0.0239 0.8213 17.2173 0.7188 0.9439
F11 0.9822 6.7482 0.0039 0.0004 0.7794 21.5433 0.5929 0.8184
F12 0.9234 4.6596 0.2341 0.0288 0.8199 16.646 0.7285 0.9503
F13 0.8719 4.1596 0.2554 0.0305 0.8119 15.5832 0.6670 0.8744
F14 0.7603 3.4486 0.3242 0.0377 0.8103 14.7868 0.6277 0.8273
F15 0.6526 2.6020 0.3952 0.0472 0.8065 12.9358 0.6009 0.7698
F16 0.8479 3.9697 0.2804 0.0338 0.8529 16.0637 0.6703 0.8724
F17 0.9259 5.1284 0.2094 0.0252 0.8250 18.4020 0.7133 0.9529
F18 0.8077 3.4207 0.3343 0.0405 0.8541 14.5495 0.6652 0.8542
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